Abstract:Abstract Metastatic breast cancer is the second most common cause of cancer-related death in women. Triple Negative Breast Cancer (TNBC) has tan especially poor prognosis partly due to these tumors lacking relevant molecular targets. The most commonly mutated gene in TNBC is the tumor suppressor TP53. Mostly, p53 mutations give rise to stably expressed proteins with tumor promoting functions. Therefore, there is an urgent need for therapeutics that can target p53-mutated TNBCs. Here we show that an anti-senescence compound can target metastatic cancers. We found that, in TNBCs, mutant p53 attained a distinctive conformation that has novel oncogenic roles through binding to the transcription factor Forkhead box O (FOXO) 4 sequestered within promyelocytic leukemia (PML) foci. Since these nuclear structures are specific to senescent cells, we tested the senolytic FOXO4 peptide. In cytotoxicity experiments, we found this compound to target TNBCs specifically over other breast cancer subtypes. Most importantly, these compounds decrease metastatic burden in the most commonly-used mouse model for human breast cancer metastasis. In summary, our results demonstrate that mutant p53-driven cancers presented senescent cell-specific characteristics that makes them a great candidate for the FOXO4-directed anti-senescence therapy. We expect that creative repurposing of senolytics to translate to other types of cancer that are driven by mutant p53. Citation Format: Diana Putavet, Marjolein Baar, Tao Shi, Johannes Lehmann, Tim Leyten, Esmee Bouma, Antoine Khalil, Harm-Jan Vos, Boudewijn Burgering, Tobias Dansen, Patrick Derksen, Peter de Keizer. Repurposing the FOXO4 senolytic against triple-negative breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-19-02.

Selective Elimination of Senescent Cancer Cells by Galacto-Modified PROTACs

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Senolytic Prodrugs: A Promising Approach to Enhancing Senescence-Targeting Intervention

Senolysis Enabled by Senescent Cell‐Sensitive Bioorthogonal Tetrazine Ligation

Abstract P1-19-02: Repurposing the FOXO4 senolytic against triple-negative breast cancer

A versatile drug delivery system targeting senescent cells

A Senolysis-Based Theragnostic Prodrug Strategy Towards Chronic Renal Failure

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Cancer Selective Target Degradation By Folate-Caged Protacs

PROTAC as a novel anti-cancer strategy by targeting aging-related signaling

Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Exploiting senescence for the treatment of cancer

Targeted Clearance of Senescent Cells via Engineered Extracellular Vesicles Reprograms Tumor Immunosuppressive Microenvironment

Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis

Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects

Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Development of PROTAC Degrader Drugs for Cancer